1389355-33-2

Basic information

• Product Name: N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine
• Synonyms: N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine
• CAS NO: 1389355-33-2
• Molecular Weight: 391.229
• Mol File: 1389355-33-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine(1389355-33-2)
• EPA Substance Registry System: N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine(1389355-33-2)

Safety Data

• Hazardous Substances Data: 1389355-33-2(Hazardous Substances Data)

Upstream product

• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 113426-12-3 [(18)F]-2-fluoroethyltosylate 
• 295330-61-9 4-[(3-bromophenyl)amino]-6-hydroxy-7-methoxyquinazoline 
• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 
• 20323-74-4 2-carboethoxy-4,5-dimethoxyaniline 
• 295330-64-2 4-[(3-bromo-phenyl)amino]-6-methylcarbonyloxy-7-methoxy-quinazoline 

Relevant articles and documents

Model 18 F mark 4-amino-quinazoline derivatives and its preparation method and tumor PET imaging applications

The invention provides novel F marked 4-aminoquinazoline compounds. The novel F marked 4-aminoquinazoline compounds are characterized in that one end of each of the novel F marked 4-aminoquinazoline compounds has a F substituted alkyloxy structure; the other end of each of the compounds has a 6,7-substituted quinazoline structure, and a substituent R1 is positioned in the 3 position of a 4-aminobenzene ring which is the quinazoline maternal, and is H, F, Cl, Br, I, a trifluoromethyl group or an acetenyl group; a substituent R2 is positioned in the 4 position of the 4-aminobenzene ring which is the quinazoline maternal, and is H, F, Cl, Br, a methyl group, a methoxy group, a 3-fluorophenoxyl group, or a 2-pyridyloxy group; and n is 1-5. The structural formula of the compounds is shown as A in the specification. Results of experiments show that the precursor of the marker of the compounds is easy to synthesize, marks through using a two-step method and has a high marking rate. The compounds have a good bioactivity, for example, the compounds have high absorption and slow removal in tumor tissues and low intake and fast removal in normal tissues and blood, so the compounds have a high tumor/background ratio, and especially have a high tumor/blood ratio, a high tumor/flesh ratio and a high tumor/brain ration, are in favor of the PET tumor development, and perform a huge potential as a brain tumor developer.